Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|6|1048-1054

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.6, 2015-06, pp. : 1048-1054

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 3005-3014

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is allogeneic transplantation really the best treatment for FLT3/ITD‐positive acute myeloid leukemia? A systematic review

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 2, 2015-02 ,pp. : 149-160

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy

By  

Acta Haematologica, Vol. 124, Iss. 3, 2010-10 ,pp. : 153-159

Karger

Access to resources Recommend Favorite

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 2, 2018-02 ,pp. : 222-231

John Wiley & Sons Inc

Access to resources Recommend Favorite

Independent oncogenic and therapeutic significance of phosphatase PRL‐3 in FLT3‐ITD–negative acute myeloid leukemia

By  

CANCER, Vol. 120, Iss. 14, 2014-07 ,pp. : 2130-2141

John Wiley & Sons Inc

Access to resources Recommend Favorite